DAsatinib DIscontinuation for 1st-Line treatment with Chronic Myelogenous Leukemia-Chronic Phase with One Year Complete Molecular Remission
Latest Information Update: 29 Aug 2019
At a glance
- Drugs Dasatinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Acronyms DADI; IMIDAS-4
- 29 Aug 2019 Status changed from recruiting to completed, according to results presented at the 24th Congress of the European Haematology Association.
- 07 Nov 2013 New trial record